Aug 20 (Reuters) - Eli Lilly ( LLY ) said on Tuesday its

weight loss drug cut the risk of developing diabetes by 94% in

patients with pre-diabetes or those who were obese or overweight

in a long-term study.

Treatment with tirzepatide, which is the active ingredient

in Lilly's Zepbound and Mounjaro treatments, also resulted in

22.9% average decrease in body weight compared to 2.1% for

placebo, the company said.